Drug Trial Radar · NCT01052480
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
Last checked: Nov 20, 2026Latest source record: Sep 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
Dec 2010
Primary completion
Mar 2015
Study completion Nov 2015
Sponsor
- Sponsor type
- NIH
- First posted
- Jan 20, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B. Hospitalized subjects with influenza A or B that have either a low oxygen level or a high respiratory rate will be eligible for study participation. This study will enroll adults, children and pregnant women.
Conditions
- Influenza A
- Influenza B
Interventions
Anti-Influenza Immune PlasmaBiological
2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
Standard CareDrug
All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Normalization of Respiratory Status (Primary Efficacy Population)Time frame: Measured from Day 0 through Day 28
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
David Geffen School of Medicine at UCLA
Los Angeles, California
Naval Medical Center San Diego
San Diego, California
Los Angeles Biomedical Research Institute, CA
Torrance, California
Children's National Medical Center
Washington D.C., District of Columbia
Washington, DC VA Med Center
Washington D.C., District of Columbia
University of Florida
Gainesville, Florida
Emory University Hospital
Atlanta, Georgia
Northwestern University (NU)
Chicago, Illinois
The Rush University Medical Center
Chicago, Illinois
University of Maryland School of Medicine Center for Vaccine Development
Baltimore, Maryland
John Hopkins University (JHU)
Baltimore, Maryland
Walter Reed National Military Medical Center (WRNMMC)
Bethesda, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital/Harvard Medical School
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Boston Med Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
University of Massachusetts Medical School
Worcester, Massachusetts
University of Michigan
Ann Arbor, Michigan
Bronson Healthcare Group
Kalamazoo, Michigan
Saint Mary's Hospital (Mayo Clinic)
Rochester, Minnesota
Mount Sinai Medical Center
New York, New York
Cornell Clinical Trials Unit, New York Presbyterian Hospital, Weill Cornell Medical College
New York, New York
Montefiore Medical Center/Albert Einstein College of Medicine
New York, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
University of Cincinnati College of Medicine
Cincinnati, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania
Texas Tech University Health Science Center (HSC)- Amarillo
Amarillo, Texas
Texas Children's Hospital
Houston, Texas
Texas Tech HSC-Lubbock, TX
Lubbock, Texas
Naval Medical Center Portsmouth
Portsmouth, Virginia
Madigan Army Medical Center (MAMC)
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.